+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison of two Cisplatin based doublets in advanced non-small cell lung cancer



Comparison of two Cisplatin based doublets in advanced non-small cell lung cancer



EJC Suppl.s 1(5): S232




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034624535

Download citation: RISBibTeXText


Related references

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. Journal of Clinical Oncology 21(17): 3207-3213, 2003

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer. Medicine 94(27): E1072, 2015

Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials. Lung Cancer 76(2): 222-227, 2012

Gemcitabine-based doublets for advanced non-small-cell lung cancer: beyond gemcitabine/cisplatin. Clinical Lung Cancer 3(Suppl. 1): S10-S16, 2002

Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naive advanced non-small-cell lung cancer in the era of third-generation agents. 2012

Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents. Journal of Cancer Research and Clinical Oncology 139(1): 25-38, 2013

Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer. Clinical Lung Cancer 15(2): 166-170, 2014

Cisplatin/gemcitabine vs cisplatin/gemcitabine/vinorelbine vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine in advanced non-small cell lung cancer Final results of a Spanish lung cancer group phase III trial. European Journal of Cancer 37(Suppl. 6): S28, 2001

Comparison of cisplatin plus vindesine with cisplatin plus mitomycin C for treatment of advanced non-small-cell lung cancer. The Eastern Shikoku Lung Cancer Chemotherapy Group. Oncology 50(1): 5-9, 1993

Cisplatin(P)-including triplets versus P-free doublets in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC): SICOG 0101 randomized trial. Journal of Clinical Oncology 24(18_Suppl): 7103-7103, 2016

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. Journal of Clinical Oncology 18(6): 1351-1359, 2000

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. Journal of Clinical Oncology 20(21): 4285-4291, 2002

Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer. Medical Oncology 28(4): 1418-1424, 2011

ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p). Journal of Clinical Oncology 23(16_Suppl): 7002-7002, 2016

Comparison of cisplatin plus vindesine with cisplatin plus mitomycin C for treatment of advanced non-small-cell lung cancer. Oncology (basel). 50(1): 5-9, 1993